Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset Seizures

@article{BenMenachem2007EfficacyAS,
  title={Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset Seizures},
  author={Elinor Ben-Menachem and Victor Biton and Dalius Jatu{\vz}is and Bassel Abou-Khalil and Pamela Doty and G. David Rudd},
  journal={Epilepsia},
  year={2007},
  volume={48}
}
Summary:  Purpose: To evaluate the efficacy and safety of lacosamide when added to 1 or 2 antiepileptic drugs (AEDs) in adults with uncontrolled partial‐onset seizures, and assess plasma concentrations of concomitant AEDs to determine any potential for drug interactions. 
Lacosamide as adjunctive therapy for partial‐onset seizures: A randomized controlled trial
TLDR
The objective is to evaluate the efficacy and safety of lacosamide as adjunctive treatment in patients with uncontrolled partial‐onset seizures taking one to three concomitant antiepileptic drugs (AEDs).
Adjunctive lacosamide for partial‐onset seizures: Efficacy and safety results from a randomized controlled trial
TLDR
To evaluate the efficacy and safety of lacosamide when added to one to three concomitant antiepileptic drugs (AEDs) in patients with uncontrolled partial‐onset seizures.
Once-daily USL255 as adjunctive treatment of partial-onset seizures: Randomized phase III study
To evaluate the efficacy and safety of USL255, Qudexy™ XR (topiramate) extended‐release capsules, as an adjunctive treatment for refractory partial‐onset seizures (POS) in adults taking one to three
Long‐term adjunctive lacosamide treatment in patients with partial‐onset seizures
To evaluate long‐term (up to 5.5 years) safety, seizure reduction, and maintenance of efficacy of the antiepileptic drug (AED) lacosamide as adjunctive treatment in an open‐label extension trial
Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide‐naive patients with partial‐onset seizures
Purpose:  To examine the safety and tolerability of rapidly initiating adjunctive lacosamide via a single intravenous loading dose followed by twice‐daily oral lacosamide in lacosamide‐naive adults
Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy
Lacosamide (LCM) is a novel antiepileptic drug (AED) with potential benefit as adjunctive treatment in patients with partial‐onset seizures. As yet, limited information on cognitive effects of LCM is
Long‐term safety and efficacy in patients with uncontrolled partial‐onset seizures treated with adjunctive lacosamide: Results from a phase III open‐label extension trial
TLDR
To evaluate the long‐term safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial‐onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open‐label extension trial SP756 (NCT00522275).
Intravenous lacosamide as replacement for oral lacosamide in patients with partial‐onset seizures
TLDR
The safety, tolerability, and pharmacokinetics of intravenous Lacosamide as replacement for oral lacosamide in patients with partial‐onset seizures were evaluated.
Long‐term exposure and safety of lacosamide monotherapy for the treatment of partial‐onset (focal) seizures: Results from a multicenter, open‐label trial
To assess long‐term use and safety of lacosamide (LCM) ≤800 mg/day monotherapy in patients with partial‐onset seizures (POS) enrolled previously in a historical‐controlled, conversion‐to‐monotherapy
Lacosamide cardiac safety: clinical trials in patients with partial‐onset seizures
TLDR
The aim is to evaluate the cardiac safety of adjunctive lacosamide in a large pool of adults with partial‐onset seizures (POS) and to establish a smoking cessation protocol for this drug.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
New antiepileptic drugs: a systematic review of their efficacy and tolerability
TLDR
Each drug was significantly better than placebo at preventing seizures, but none was significantly different from the others in terms of efficacy or tolerability, though the confidence intervals were wide Randomised trials comparing active treatments are needed to further evaluate these drugs.
The Use of Antiepileptic Drugs—Principles and Practice
Summary:  Up to 70% of people developing epilepsy may expect to become seizure free with optimum antiepileptic drug (AED) therapy. The remaining 30% are the most difficult to treat. Most patients are
Effects of the Novel Antiepileptic Drug Lacosamide on the Development of Amygdala Kindling in Rats
TLDR
The kindling model is used to evaluate whether the novel AED lacosamide affects kindling‐induced epileptogenesis, and this drug does not seem to act by any of the mechanisms of currently available AEDs, but the exact molecular mechanisms of action have not yet been clarified.
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)
TLDR
Information presented on drugs in preclinical and clinical development, including carabersat, CGX-1007 (Conantokin-G), pregabalin, retigabine (D-23129), safinamide, SPD421 (DP-VPA), SPM 927, talampanel and valrocemide are summarized.
Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation
TLDR
Comparisons among AEDs and VNS using similar data from standard types of clinical trials allow comparisons to help physicians and patients select among the options for treatment.
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
TLDR
This article summarizes the information presented on drugs in development, including atipamezole, BIA-2-093, fluorofelbamate, NPS 1776, pregabalin, retigabine, safinamide, SPM 927, stiripentol, talampanel,ucb 34714 and valrocemide, as well as updates on second-generation AEDs.
Lacosamide: a review of preclinical properties.
TLDR
It was found that LCM selectively enhances slow inactivation of voltage-gated sodium channels without affecting fast inactivation, and collapsin-response mediator protein 2 (CRMP-2 alias DRP-2) was identified as a binding partner.
Seeking a mechanism of action for the novel anticonvulsant lacosamide
TLDR
Evidently LCM perturbs excitability in primary cortical cultures but does not appear to do so via a high-affinity interaction with an acknowledged recognition site on a target for existing antiepileptic drugs.
Dissociative and Associated Psychopathological Symptoms in Patients with Epilepsy, Pseudoseizures, and Both Seizure Forms
Summary:  Purpose: A controversy currently exists regarding the significance of dissociation and conversion in the pathogenesis of pseudoepileptic seizures. After the abolition of the term
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
TLDR
This article summarizes the information presented on drugs in development, including brivaracetam, eslicarbazepine acetate, fluorofelbamate, ganaxolone, huperzine, lacosamide, retigabine, rufinamide, seletracetam, stiripentol, talampanel, valrocemide, JZP-4, NS1209, PID and RWJ-333369.
...
1
2
...